COYA Coya Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835022 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.6%
TTM net income YoY-63.7%
TTM EPS YoY-25.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-675.3%
Net margin-643.5%
FCF margin—
EBITDA margin-675.0%
Returns
ROE-99.2%
ROA-84.6%
ROIC (approx.)—
Asset turnover0.13x
Leverage & solvency
Liabilities / assets14.6%
Debt / equity0.00x
Current ratio7.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-23.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.95M | $3.55M |
| R&D expense | $16.73M | $11.87M |
| SG&A expense | $11.45M | $8.89M |
| Operating income | -$22.56M | -$17.25M |
| Pretax income | -$21.22M | -$15.60M |
| Income tax | $3,089 | -$720,287 |
| Net income | -$21.23M | -$14.88M |
| EBITDA | -$22.53M | -$17.22M |
| EPS (basic) | -1.27 | -0.98 |
| EPS (diluted) | -1.27 | -0.98 |
| Weighted avg. shares (diluted) | 16.73M | 15.24M |
| Balance sheet | ||
| Cash & equivalents | $46.82M | $38.34M |
| Current assets | $49.94M | $44.31M |
| PP&E, net | $11,227 | $38,588 |
| Total assets | $49.95M | $44.35M |
| Current liabilities | $5.87M | $3.82M |
| Total liabilities | $6.92M | $4.77M |
| Shareholders' equity | $43.03M | $39.58M |
| Shares outstanding | 20.93M | 16.71M |
| Cash flow statement | ||
| Operating cash flow | -$10.74M | -$10.29M |
| Investing cash flow | -$1.16M | -$25,000 |
| Financing cash flow | $20.39M | $16.03M |
| Depreciation & amortization | $27,361 | $27,361 |
| Stock-based compensation | $4.29M | $2.66M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.